New Publications From the Smith Breast Center

Archive

November - December 2006

Martin, M.D., Hilsenbeck, S.G., Mohsin, S.K., Hopp, T.A., Clark, G.M., Osborne, C.K., Allred, D.C., O’Connell, P.  Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.  Breast Cancer Res Treat 95(1):7-12, 2006. [PDF]

Wang, L.H., Yang, X.Y., Zhang, X., An, P., Kim, H.J., Huang, J., Clarke, R., Osborne, C.K., Inman, J.K., Appella, E., Farrar, W.L.  Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.  Cancer Cell 10(6):487-499, 2006. [PDF]

Massarweh S, Schiff R.  Resistance to endocrine therapy in breast cancer:  exploiting estrogen receptor/growth factor signaling crosstalk.  Endocr Relat Cancer.  2006 Dec; 13 Suppl 1:S15-24. [PDF]

Du, Z., Podsypanina, K., Huang, S., McGrath, A., Toneff, M.J., Bogoslovskaia, E., Zhang, X., Moraes, R.C., Fluck, M., Allred, D.C. Lewis, M.T., Varmus, H.E., and Li, Y. (2006) “Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models” Proc. Natl. Acad. Sci. 103:17396-401 [PDF]

Shixia Huang, Katrina Podsypanina, Yidong Chen, Weiyan Cai, Anna Tsimelzon, Susan Hilsenbeck, Yi Li. Wnt-1 is dominant over Neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 5: 565- 571, 2006 [PDF]

September - October 2006

Ma X-J, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG.  The HOXB13:IL17BR expression index is a prognostic factor in early stage breast cancer.  JCO 24(28):4611-4619, 2006.

Leen AM, Myers GG, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.  Nature Med 12(10):1160-1166, 2006.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV.  The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.  Breast Cancer Res Treat 98(3):315-327, 2006.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.  Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.  Cancer Res 66(16):8366-8273, 2006.

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC.  Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12(17):5047-5054, 2006.

Townson SM, Kang K, Lee AV, Oesterreich S.  Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells.  Biochem Biophys Res Commun 349(2):540-8, 2006.

Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SAW.  Metastasis-associated protein 2 is a repressor of estrogen receptor whose overexpression leads to estrogen-independent growth of human breast cancer cells.  Mol Endocrinol 20:2020-2035, 2006.

Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang Z-Y, Nicholson R, Fuqua SAW.  Elevated expression of MAPK phosphastase 3 in breast cancer: A mechanism of tamoxifen resistance.  Cancer Res 66:5950-5959, 2006.

Ramos CA, Bowman TA, Boles NC, Merchant AA, Zheng Y, Parra I, Fuqua SAW, Shaw CA, Goodell MA.  Evidence for diversity in transcriptional profiles of single hematopoietic stem cells.  PLoS Genetics 2:1487-1499, 2006.

July - August 2006

Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, Kramer RM.  The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J Support Oncol 4:295-8, 304, 2006.

Lee AV, Weiss H, Cui X, Osborne CK, Arpino G, Schiff R. In reply. J Clin Oncol 24:2595-2597, 2006.

Dobrzycka KM, Kang K, Jiang S, Meyer R, Rao PH, Lee AV, Oesterreich S.  Disruption of Scaffold Attachment Factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of senescence, and cell immortalization.  Cancer Res 66:7859-63, 2006

Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J.  Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 147:3877-88, 2006.

May - June 2006

Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol Apr 4, 2006 [Epub Ahead Of Print].

Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66:5950-5959, 2006.

Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother 29:250-260, 2006.

Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplant. Blood, June 1, 2006 [Epub ahead of print].

Grimm SL, Bu W, Longley MA, Roop DR, Li Y, Rosen JM. Keratin 6 is not essential for mammary gland development. Breast Cancer Res Jun 21, 2006 8(3):R29 [Epub ahead of print]

Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA. Metastasis-Associated Protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol Apr 27, 2006; [Epub ahead of print].

Onken B, Weiner H, Philips M, Chang EC. Compartmentalized signaling of Ras in fission yeast. Proc Natl Acad Sci USA 103:9045-9050, 2006.

Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 66:5304-13, 2006.

Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology May 18, 2006 [Epub ahead of print].

March – April 2006

Elledge R.  Tales from a targeted therapy – Editorial.  J Clin Oncol 24; 1323-25: 2006.

Wu K, DuPre E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH.  Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.  Breast Cancer Res Treat 96: 147-57, 2006.

Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM.  Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.  Biochem J 395: 653-62, 2006.

Singh RR, Barnes CJ, Talukder AH, Fuqua SAW, Kumar R.  Negative regulation of ERa trans­activation functions by LIM-only protein LM04.  Cancer Res 65: 10594-10601, 2005.

Poola I, Fuqua SAW, DeWitty RL, Abraham J, Marshallack JJ, Liu A:  ERa-negative breast cancer tissues express significant levels of estrogen independent transcription factors, ERβ1 and ERβ5:  Potential molecular targets for chemoprevention.  Clin Cancer Res 11: 7579-7582, 2005.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Mar 16; [Epub ahead of print] 

Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? Nat Clin Pract Oncol. 2006 Mar;3(3):134-5.

Bourgogne A, Hilsenbeck SG, DunnyGM, Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the fsr system of enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol 188:2875-2884, 2006

January – February 2006

Martin M.D., Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P.  Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.  Breast Cancer Res Treat 95:7-12, 2006.

Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC.  Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer.  Breast Cancer Res 8:R6, 2006.

Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C.  Proceedings of the fifth international conference on recent advances and future directions in endocrine therapy for breast cancer: conference summary statement.  Clin Cancer Res 12:997s-1000s, 2006.

Kim HJ, Cui X, Hilsenbeck SG, Lee AV.  Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.  Clin Cancer Res 12:1-13s-1018s, 2006.

Hilsenbeck SG, Osborne CK.  Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? an in silico clinical trial.  Clin Cancer Res 12:1049s-1055s, 2006.